Skip to main content
Signal8

Liminatus Pharma, Inc. (LIMN) Form 10-Q — May 15, 2026

$LIMNForm 10-QFiled May 15, 2026, 4:49 PM ET0001104659-26-062734Original filing

Liminatus Pharma reported a net loss of $1.12 million for the first quarter of 2026, driven by increased general and administrative expenses and new research and development costs for its IBA101 candidate. The company ended the quarter with only $1.9 million in cash and an accumulated deficit of nearly $40 million, prompting management to disclose substantial doubt about its ability to continue as a going concern. The filing reveals significant governance and listing risks, including material weaknesses in internal controls over financial reporting due to inadequate segregation of duties and lack of formalized oversight.

Key figures

Revenue
0
Total Debt
1442500
Cash Position
1907674
Shares Outstanding
44877633
Offering price
0.29
Warrant liability
33422
Related party debt
1442500
Accumulated deficit
-39995447
Offering net proceeds
3440000
Shares offered common
8270000
Shares offered warrants
13813000
Deferred underwriting fee payable
500000
Shares offered prefunded warrants
5543000

Price after filing

1 day: 0.0%7 days: +33.7%30 days: -26.1%

Close on the filing date to close N calendar days later (from $0.18). Historical, not a forecast.

AI analysis

Red flags7 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.